-
公开(公告)号：US20110305722A1
公开(公告)日：2011-12-15
申请号：US13182037
申请日：2011-07-13
IPC分类号： A61K39/385 , A61P37/04 , C07K14/76 , A61P35/00 , C07K7/06 , G01N33/566
CPC分类号： C07K14/4748 , A61K38/00
摘要： This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ∃2 microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.
摘要翻译： 本发明涉及衍生自MAGE-C2的分离的肽，编码MAGE-C2的核酸分子和来自MAGE-C2的分离的肽，包含核酸分子的表达载体，用核酸分子转化或转染的宿主细胞 表达载体和包含肽，HLA分子，∃2微球蛋白和第一和第二结合配偶体的四聚体。 本发明还涉及使用本发明的肽，核酸分子，表达载体，四聚体和复合物以及识别与HLA分子复合的肽的细胞溶解性T细胞的方法。
-
42.发明授权Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules 有权衍生自与HLA-A2分子复合的法师肿瘤排斥抗原前体的分离的肽公开(公告)号：US06682731B1
公开(公告)日：2004-01-27
申请号：US09533499
申请日：2000-03-23
申请人： Alan Townsend , Judy Bastin , Thierry Boon-Falleur , Pierre Van Der Bruggen , Pierre Coulie , Thomas Gajewski , Cornelis J. M. Melief , Marjan J. W. Visseren , Martin W. Kast
发明人： Alan Townsend , Judy Bastin , Thierry Boon-Falleur , Pierre Van Der Bruggen , Pierre Coulie , Thomas Gajewski , Cornelis J. M. Melief , Marjan J. W. Visseren , Martin W. Kast
IPC分类号： A61K4500
CPC分类号： C07K14/705 , A61K38/00 , A61K39/00 , A61K2039/5158 , C07K14/4748
摘要： Complexes of SEQ ID NO: 12 and HLA-A2 can be used to generate CTLs. They can be supplemented with IL-6 and IL-12.
摘要翻译： 可以使用SEQ ID NO：12和HLA-A2的复合物来产生CTL。 可补充IL-6和IL-12。
-
43.发明授权Isolated nucleic acid molecule encoding peptides which form complexes with MHC molecules HLA-Cw*1601 and uses thereof 失效编码与MHC分子HLA-Cw * 1601形成复合物的肽的分离的核酸分子及其用途公开(公告)号：US06465184B1
公开(公告)日：2002-10-15
申请号：US09435524
申请日：1999-11-08
申请人： Pascale Bo{haeck over (e)}l , Claude Wildmann , Thierry Boon-Falleur , Pierre van der Bruggen , Pierre Coulie , Jean-Christophe Renauld
发明人： Pascale Bo{haeck over (e)}l , Claude Wildmann , Thierry Boon-Falleur , Pierre van der Bruggen , Pierre Coulie , Jean-Christophe Renauld
IPC分类号： C12Q168
CPC分类号： C07K14/4748 , A61K38/00 , C07K14/70539
摘要： A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
摘要翻译： 公开了一系列肿瘤排斥抗原前体和编码它们的核酸分子。 这些肿瘤排斥抗原前体被称为BAGE肿瘤排斥抗原前体，编码它们的核酸分子被称为BAGE编码分子。 描述了编码序列和肿瘤排斥抗原前体分子的各种诊断和治疗用途。
-
44.发明授权Isolated protein processed to peptides which form complexes with HLA molecules 失效分离的蛋白质加工成与HLA分子形成复合物的肽公开(公告)号：US06245333B1
公开(公告)日：2001-06-12
申请号：US09179281
申请日：1998-10-26
IPC分类号： A61K3900
CPC分类号： C12Q1/6881 , A61K39/00 , C07K14/4748 , C07K14/70539 , C12Q1/6886 , C12Q2600/172 , G01N33/56977
摘要： A nucleic acid molecule which codes for a tumor rejection antigen precursor which is in turn processed to antigens presented by an HLA molecule is described. The HLA molecule may be HLA-A2, HLA-A28, HLA-B13, HLA-B44, or HLA-Cw6. The antigens are also described. These materials are useful in diagnostic and therapeutic methodologies. The tumor rejection antigen precursor is not tyrosinase, which has previously been identified as a tumor rejection antigen precursor processed to an antigen presented by HLA-B44.
摘要翻译： 描述了编码肿瘤排斥抗原前体的核酸分子，其又被加工成由HLA分子呈递的抗原。 HLA分子可以是HLA-A2，HLA-A28，HLA-B13，HLA-B44或HLA-Cw6。 还描述了抗原。 这些材料可用于诊断和治疗方法。 肿瘤排斥抗原前体不是酪氨酸酶，其先前已经被鉴定为被HLA-B44呈递的抗原加工的肿瘤排斥抗原前体。
-
45.发明授权
公开(公告)号：US5977300A
公开(公告)日：1999-11-02
申请号：US531864
申请日：1995-09-21
IPC分类号： G01N33/50 , A61K31/00 , A61K35/14 , A61K38/00 , A61K39/00 , A61P35/00 , C07H21/04 , C07K7/06 , C07K14/47 , C07K14/705 , C07K14/74 , C12N1/21 , C12N5/02 , C12N5/06 , C12N5/08 , C12N5/10 , C12N15/09 , C12P21/02 , C12Q1/68 , C12R1/91 , G01N33/569 , A61K38/08
CPC分类号： C12Q1/6881 , C07K14/4748 , C07K14/70539 , C12Q1/6886 , G01N33/56977 , A61K39/00 , C12Q2600/112
摘要： Tumor rejection antigens presented by HLA-B44 molecules are described. These peptides are useful in diagnostic and therapeutic methodologies. The tumor rejection antigens are not derived from tyrosinase, which has previously been identified as a tumor rejection antigen precursor processed to an antigen presented by HLA-B44.
摘要翻译： 描述了由HLA-B44分子呈递的肿瘤排斥抗原。 这些肽可用于诊断和治疗方法。 肿瘤排斥抗原不是源自酪氨酸酶，酪氨酸酶先前被鉴定为被HLA-B44呈递的抗原加工的肿瘤排斥抗原前体。
-
公开(公告)号：US5585461A
公开(公告)日：1996-12-17
申请号：US217186
申请日：1994-03-24
CPC分类号： C07K14/4748 , A61K38/00 , Y10S530/828 , Y10S530/865
摘要： Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
-
47.发明授权Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors 失效分离的编码BAGE肿瘤排斥抗原前体的核酸分子
公开(公告)号：US5571711A
公开(公告)日：1996-11-05
申请号：US79110
申请日：1993-06-17
IPC分类号： C12N15/09 , A61K38/00 , A61P35/00 , C07H21/02 , C07H21/04 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/74 , C12N1/21 , C12N5/10 , C12N15/12 , C12P21/02 , C12R1/91 , C12P19/34 , C12N1/15 , C12N1/19 , C12N5/00 , C12N15/00
CPC分类号： C07K14/4748 , C07K14/70539 , A61K38/00
摘要： A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
摘要翻译： 公开了一种新的肿瘤排斥抗原前体家族及其编码的核酸分子。 这些肿瘤排斥抗原前体被称为BAGE肿瘤排斥抗原前体，编码它们的核酸分子被称为BAGE编码分子。 描述了编码序列和肿瘤排斥抗原前体分子的各种诊断和治疗用途。
-
公开(公告)号：US20090233315A1
公开(公告)日：2009-09-17
申请号：US12387884
申请日：2009-05-08
IPC分类号： G01N33/567 , C07K7/06
CPC分类号： C07K14/4748 , A61K38/00
摘要： This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ∃2 microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.
摘要翻译： 本发明涉及衍生自MAGE-C2的分离的肽，编码MAGE-C2的核酸分子和来自MAGE-C2的分离的肽，包含核酸分子的表达载体，用核酸分子转化或转染的宿主细胞 表达载体和包含肽，HLA分子，∃2微球蛋白和第一和第二结合配偶体的四聚体。 本发明还涉及使用本发明的肽，核酸分子，表达载体，四聚体和复合物以及识别与HLA分子复合的肽的细胞溶解性T细胞的方法。
-
49.发明授权公开(公告)号：US06339149B1
公开(公告)日：2002-01-15
申请号：US09131831
申请日：1998-08-11
IPC分类号： C07H504
CPC分类号： C07K14/4748 , A61K38/00 , C12Q1/6886 , C12Q2600/158 , Y10S530/828
摘要： A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as DAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as GAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigens, and their precursor molecules are described.
摘要翻译： 公开了一种新的肿瘤排斥抗原前体家族及其编码的核酸分子。 这些肿瘤排斥抗原前体被称为DAGE肿瘤排斥抗原前体，编码它们的核酸分子被称为GAGE编码分子。 描述了编码序列和肿瘤排斥抗原及其前体分子的各种诊断和治疗用途。
-
公开(公告)号：US06297050B1
公开(公告)日：2001-10-02
申请号：US09322360
申请日：1999-05-28
IPC分类号： C12N508
CPC分类号： C07K14/4748 , A61K38/00 , C12Q1/6886 , C12Q2600/158 , Y10S530/828
摘要： A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as DAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as GAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigens, and their precursor molecules are described.
摘要翻译： 公开了一种新的肿瘤排斥抗原前体家族及其编码的核酸分子。 这些肿瘤排斥抗原前体被称为DAGE肿瘤排斥抗原前体，编码它们的核酸分子被称为GAGE编码分子。 描述了编码序列和肿瘤排斥抗原及其前体分子的各种诊断和治疗用途。
-
-
-
-
-
-
-
-
-
搜索结果
161 条记录 (耗时 0.037 秒)
